4 research outputs found
Design of Effisayil™ 2: A randomized, double-blind, placebo-controlled study of spesolimab in preventing flares in patients with generalized pustular psoriasis
INTRODUCTION: Generalized pustular psoriasis (GPP) is a rare autoinflammatory skin disease characterized by flares of widespread erythema with sterile pustules, and can be relapsing with recurrent flares, or persistent with intermittent flares. Spesolimab, a humanized anti-interleukin-36 (IL-36) receptor monoclonal antibody, targets the key IL-36 pathogenetic pathway in GPP. A previous study showed that spesolimab treatment led to rapid pustular and skin clearance in patients with GPP flares, which was sustained for up to 12 weeks. This study investigates the long-term effects of spesolimab on GPP flares, for which no specific treatments are currently available. The Effisayil™ 2 study will assess whether maintenance treatment with subcutaneous spesolimab prevents the occurrence of GPP flares and determine the optimal dosing regimen to achieve this aim.
METHODS: Patients will have a documented history of GPP with a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score of 0 or 1 (clear or almost clear) at screening and randomization. Patients will be randomized 1:1:1:1 to three groups receiving a 600-mg subcutaneous loading dose of spesolimab followed by a 300-mg maintenance dose administered every 4 or 12 weeks, or a 300-mg loading dose followed by a 150-mg maintenance dose administered every 12 weeks, and one group receiving placebo, for 48 weeks. The primary endpoint is time to first GPP flare. If a patient experiences a GPP flare during the randomized maintenance treatment period, an open-label intravenous dose of 900-mg spesolimab will be administered, with an option for a second intravenous dose after 1 week.
CONCLUSIONS: Effisayil™ 2 is the first placebo-controlled study in patients with GPP to investigate whether maintenance treatment with spesolimab can prevent flares and provide sustained disease control. This study will provide valuable insights on the long-term management of patients with this potentially life-threatening skin disease.
TRIAL REGISTRATION NUMBER: NCT04399837
Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare
Introduction: Generalized pustular psoriasis (GPP) is a rare, potentially life-threatening disease characterised by recurrent flares of widespread neutrophilic aseptic skin pustular eruption. Despite the availability of approved biologics for GPP in Japan, Taiwan and Thailand, associated evidence is largely based on uncontrolled studies in which acute flares were not directly assessed. Therefore, there is a high unmet need to investigate new rapid-acting effective treatments that resolve symptoms associated with acute GPP flares. A prior Phase I proof-of-concept study showed rapid improvements in skin and pustule clearance with a single intravenous dose of spesolimab, a novel anti-interleukin-36 receptor antibody, in patients presenting with an acute GPP flare. Here, we present the design and rationale of Effisayil 1, a global, Phase II, placebo-controlled study to evaluate the efficacy, safety and tolerability of spesolimab in patients presenting with an acute GPP flare.
Methods and analysis: At least 51 patients with an acute GPP flare will be randomised 2:1 to receive a single 900 mg intravenous dose of spesolimab or placebo and followed for up to 28 weeks. The primary endpoint is a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of 0 (pustule clearance) at Week 1. The key secondary endpoint is a GPPGA score of 0 or 1 (clear or almost clear) at Week 1. Safety will be assessed over the study duration by the occurrence of treatment-emergent adverse events. Blood and skin biopsies will be collected to assess biomarkers. Superiority of spesolimab over placebo in the proportion of patients achieving the primary and key secondary endpoints will be evaluated.
Ethics and dissemination: The study complies with the ethical principles of the Declaration of Helsinki, the International Council for Harmonisation’s Good Clinical Practice and local regulations. Ethics committee approvals have been obtained for each centre from all participating countries and are listed in online supplementary file 1. Primary results will be published in a peer-reviewed journal.
Trial registration details: ClinicalTrials.gov identifier: NCT03782792; Pre-results
Trial of spesolimab for generalized pustular psoriasis.
BACKGROUND:
Generalized pustular psoriasis (GPP) is a rare, life-threatening, inflammatory skin
disease characterized by widespread eruption of sterile pustules. Interleukin-36
signaling is involved in the pathogenesis of this disorder. Spesolimab, a humanized anti–interleukin-36 receptor monoclonal antibody, is being studied for the
treatment of GPP flares.
METHODS:
In a phase 2 trial, we randomly assigned patients with a GPP flare in a 2:1 ratio to
receive a single 900-mg intravenous dose of spesolimab or placebo. Patients in both
groups could receive an open-label dose of spesolimab on day 8, an open-label dose
of spesolimab as a rescue medication after day 8, or both and were followed to week
12. The primary end point was a Generalized Pustular Psoriasis Physician Global
Assessment (GPPGA) pustulation subscore of 0 (range, 0 [no visible pustules] to 4
[severe pustulation]) at the end of week 1. The key secondary end point was a GPPGA total score of 0 or 1 (clear or almost clear skin) at the end of week 1; scores
range from 0 to 4, with higher scores indicating greater disease severity.
RESULTS:
A total of 53 patients were enrolled: 35 were assigned to receive spesolimab and 18
to receive placebo. At baseline, 46% of the patients in the spesolimab group and 39%
of those in the placebo group had a GPPGA pustulation subscore of 3, and 37% and
33%, respectively, had a pustulation subscore of 4. At the end of week 1, a total of
19 of 35 patients (54%) in the spesolimab group had a pustulation subscore of 0, as
compared with 1 of 18 patients (6%) in the placebo group (difference, 49 percentage
points; 95% confidence interval [CI], 21 to 67; P<0.001). A total of 15 of 35 patients
(43%) had a GPPGA total score of 0 or 1, as compared with 2 of 18 patients (11%)
in the placebo group (difference, 32 percentage points; 95% CI, 2 to 53; P=0.02).
Drug reactions were reported in 2 patients who received spesolimab, in 1 of them
concurrently with a drug-induced hepatic injury. Among patients assigned to the
spesolimab group, infections occurred in 6 of 35 (17%) through the first week;
among patients who received spesolimab at any time in the trial, infections had occurred in 24 of 51 (47%) at week 12. Antidrug antibodies were detected in 23 of 50
patients (46%) who received at least one dose of spesolimab.
CONCLUSIONS:
In a phase 2 randomized trial involving patients with GPP, the interleukin-36 receptor inhibitor spesolimab resulted in a higher incidence of lesion clearance at 1
week than placebo but was associated with infections and systemic drug reactions.
Longer and larger trials are warranted to determine the effect and risks of spesolimab in patients with pustular psoriasis. (Funded by Boehringer Ingelheim; Effisayil 1 ClinicalTrials.gov number, NCT03782792.
Spesolimab treatment for people with flares of generalized pustular psoriasis: a plain language summary of the Effisayil™ 1 study
What is this study about?: Spesolimab is a drug developed to treat worsening disease (known as flares) of generalized pustular psoriasis (shortened to GPP). GPP is a rare disease in which pus-filled blisters or pustules suddenly form all over the body. Before a drug can be approved to treat the symptoms of a disease, clinical studies are performed to test how well it works and whether there are any side effects. This summary reports the results from a clinical study called Effisayil™ 1 that was performed to understand if spesolimab is effective at treating people with GPP flares. What were the results?: The study showed that a single dose of spesolimab rapidly cleared pustules and skin lesions (areas of skin affected by redness, pustules, and scaling) within 1 week of treatment, and continued to improve skin lesions for up to 12 weeks. Spesolimab also reduced pain and improved the quality of life of participants over time. Some participants experienced side effects, which were mostly mild or moderate. What do the results of the study mean?: The results indicate that spesolimab is an effective treatment for GPP flares. Although spesolimab is not yet available for doctors to prescribe as medication to their patients, the results of this study are currently under review by the official body that approves drugs for use in the USA